Latest muscle atrophy Stories
WALTHAM, Mass., Oct.
Patients with cystic fibrosis (CF) usually experience significant muscle loss, a symptom traditionally considered to be a secondary complication of the devastating genetic disease.
Researchers at the University of Rochester Medical Center have found a way to block the genetic flaw at the heart of a common form of muscular dystrophy.
Researchers have found a potential new treatment for the common problem of muscle atrophy. Results of the animal study were presented at The Endocrine Society's 91st Annual Meeting in Washington, D.C.
A new drug being studied for the treatment of muscle degenerating diseases has shown promising results. According to a study published today in the British Journal of Pharmacology, Debio 025 is as effective as current drugs but, crucially, does not cause unwanted immunosuppressive effects.
During desperate times, such as fasting, or muscle wasting that afflicts cancer or AIDS patients, the body cannibalizes itself, atrophying and breaking down skeletal muscle proteins to liberate amino acids.
Newly-published research from the University of Calgary suggests that muscle in obese people and Type 2 diabetes may be conspiring against them.
GTx, Inc. (NASDAQ: GTXI) today announced topline results of a Phase II clinical trial evaluating Ostarine(TM) (MK-2866), an investigational selective androgen receptor modulator (SARM), in patients with cancer induced muscle loss, also known as cancer cachexia.
Families of Spinal Muscular Atrophy (FSMA, www.curesma.org), Invitrogen Corporation (NASDAQ:IVGN)(www.invitrogen.com), and deCODE chemistry & biostructures (www.decodechembio.com) announced today they have identified a protein that is a potential molecular target for the treatment of Spinal Muscular Atrophy (SMA).
BOSTON, Sept. 10 /PRNewswire-USNewswire/ -- The U.S.